1-9 of 9
Henrik Gregersen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

Ida Bruun Bruun Kristensen, Hanne Marie Norseth, Diana Loigom, Henrik Gregersen, Einar Haukås, Tobias S. S. Slørdahl, Robert Schou Pedersen, Damian L. Szatkowski, Fredrik Schjesvold, Thomas Lund
Journal: Blood
Blood (2024) 144 (Supplement 1): 1988.
https://doi.org/10.1182/blood-2024-194840
Published: 2024
Journal Articles

Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Andrew Spencer, Katrine Fladeland Iversen, Binod Dhakal, Maria Creignou, Jenny Chen, Ida H Hiemstra, Sieto Bosgra, Avani Badani, Esther C.W. Breij, Lauren K. Brady, A. Kate Sasser, Anders Malmberg, Henrik Gregersen, Markus Hansson, Annemiek Broijl, Maria-Victoria Mateos, Torben Plesner
Journal: Blood
Blood (2022) 140 (Supplement 1): 7320–7321.
https://doi.org/10.1182/blood-2022-159116
Published: 2022
Journal Articles

The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey

Louise Redder, Sören Möller, Anna Thit Johnsen, Mary Jarden, Christen lykkegaard Andersen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Saaby Steffensen, Per Troellund Pedersen, Maja Hinge, Mikael Frederiksen, Carsten Helleberg, Niels Abildgaard, Lene Kongsgaard Nielsen
Journal: Blood
Blood (2021) 138 (Supplement 1): 1638.
https://doi.org/10.1182/blood-2021-147707
Published: 2021
Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Henrik Gregersen, MD PhD, Valdas Peceliunas, MD, Kari Remes, MD PhD, Fredrik H. Schjesvold, MD PhD, Niels Abildgaard, MD, Hareth Nahi, MD PhD, Niels Frost Andersen, MD PhD, Annette Juul Vangsted, MD PhD, Tobias Wirenfeldt Klausen, M.S., Carsten Helleberg, MD, Kristina Carlson, MD, Ulf Christian Frølund, MD, Per Axelsson, MD, Olga Stromberg, MD, Cecilie Hveding Blimark, PhD MD, Olle Linder, MD, Galina Tsykunova, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Nina Gulbrandsen
Journal: Blood
Blood (2019) 134 (Supplement_1): 601.
https://doi.org/10.1182/blood-2019-122141
Published: 2019
Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1849.
https://doi.org/10.1182/blood-2019-128074
Published: 2019
Journal Articles

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Henrik Gregersen, MD, Niels Abildgaard, MD, Trung Hieu Do, MD, Ida Bruun Kristensen, MD, Ulf Christian Frølund, MD, Niels Frost Andersen, MD, Lene Kongsgaard Nielsen, MD, Christen Lykkegaard Andersen, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3129.
https://doi.org/10.1182/blood.V130.Suppl_1.3129.3129
Published: 2017
Journal Articles

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Clinical Trials & Observations
Ulf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, Stig Lenhoff, Edward Laane, Kari Remes, Hlif Steingrimsdottir, Niels Abildgaard, Lucia Ahlberg, Cecilie Blimark, Inger Marie Dahl, Karin Forsberg, Tobias Gedde-Dahl, Henrik Gregersen, Astrid Gruber, Nina Guldbrandsen, Einar Haukås, Kristina Carlson, Ann Kristin Kvam, Hareth Nahi, Roald Lindås, Niels Frost Andersen, Ingemar Turesson, Anders Waage, Jan Westin
Journal: Blood
Blood (2013) 121 (23): 4647–4654.
https://doi.org/10.1182/blood-2012-11-464503
Published: 2013
Journal Articles

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Peter Gimsing, MD, DMSci, Assoc. Prof., Oyvind Hjertner, Niels Abildgaard, Niels Frost Andersen, Tobias Gedde Dahl, Henrik Gregersen, MD, Ulf-Henrik Mellqvist, MD, PhD, Olle Linder, Roald Lindas, Niels-Aage Tøfner Clausen, Stig Lenhoff
Journal: Blood
Blood (2011) 118 (21): 3073.
https://doi.org/10.1182/blood.V118.21.3073.3073
Published: 2011
Journal Articles

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Ulf-Henrik Mellqvist, MD, PhD, Jan Westin, MD, PhD, Peter Gimsing, DO, PhD, Oyvind Hjertner, Stig Lenhoff, MD, PhD, Edward Laane, Kari Remes, MD, PhD, Hlif Steingrimsdottir, Niels Abildgaard, Lucia Ahlberg, Kristina Carlsson, Inge Marie Dahl, Karin Forsberg, Tobias Gedde-Dahl, MD, PhD, Henrik Gregersen, Astrid Gruber, MD, PhD, Nina Guldbrandsen, Einar Haukås, Olle Linder, Hareth Nahi, Ingerid Nesthus, Nilsaage Toffner-Clausen, Raija Silvennoinen, Niels Frost Andersen, MD, Ingemar Turesson, MD, PhD, Anders Waage, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 530.
https://doi.org/10.1182/blood.V114.22.530.530
Published: 2009